A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

PHASE3RecruitingINTERVENTIONAL

Enrollment

221

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2026

Conditions

Type 2 DiabetesHypertension

Interventions

DRUG

THP-00101

Dapagliflozin 10 mg

DRUG

THP-00102

Telmisartan 80 mg

DRUG

THP-00103

Telmisartan 40 mg

DRUG

THP-00104

Placebo of Dapagliflozin 10mg

DRUG

THP-00105

Placebo of Telmisartan 80mg

DRUG

THP-00106

Placebo of Telmisartan 40mg

Trial Locations (2)

NOT_YET_RECRUITING

Thammasat University Hospital, Pathum Thani

RECRUITING

The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul

All Listed Sponsors

lead

THPharm Corp.

INDUSTRY